Document is current
Any future updates will be listed below
-
Authors
Luo, Shuqin
Ezrokhi, Michael
Cominos, Nicholas
Tsai, Tsung-Huang
Stoelzel, Carl R.
Trubitsyna, Yelena
Cincotta, Anthony H. https://orcid.org/0000-0002-8329-3341
-
Funding
Funding for this research was provided by:
VeroScience LLC
S2 Therapeutics Inc
- License Information
-
More Information
Article History
Received: 14 October 2020
Accepted: 13 January 2021
First Online: 23 January 2021
Ethics approval and consent to participate
: All animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Experimental Animals (2011) and also with the protocols approved by the Institutional Animal Care and Use Committee of VeroScience, LLC.
: All authors have read and approved the final manuscript.
: The authors declare that they have no competing interests, however the authors are past or present employees of VeroScience LLC, a company that owns Cycloset, a dopamine agonist for the treatment of type 2 diabetes.
